ImmuCell Corporation

Good morning, and welcome to MU-Shell Corporation Report's second quarter, ended June 30th, 2025, unaudited financial results conference call. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference over to Joe Diaz of ListenPartners. Please go ahead.

Thank you, and good morning to everyone. As the conference call started, Operator indicated, my name is Joe Diaz. I'm with Letham Partners. We're the investor relations consulting firm for In Yourself. Thank you again for all of us for joining us today to discuss the unaudited financial results of the second quarter ended June 30, 2025. Listeners are reminded and cautioned that statements made by management during the course of this call include forward-looking statements. which include any statement that refers to future events or expected future results or predictions about sets the company plans to take in the future. These statements are not guaranteed of performance and are subject to risks and uncertainties that could cause actual results, outcomes, or events to differ materially from those discussed today. Additional information regarding forward-looking statements and the risks and uncertainties that could impact future results outcomes or events is available under the cautionary note regarding forward-looking statements or better known as a safe harbor statement provided with form 10q and the press release that the company filed last night along with the company's other periodic fines with the sec information discussed on today's call speaks only as of today friday august 15 2025 the company undertakes no obligations to update any information discussed on today's call. Please note that references to certain non-GAAP financial measures may be made during today's call. The company included definitions of these terms as well as reconciliations of these figures to the most comparable GAAP financial measures in last night's press release in order to better assist you in understanding its financial performance. With that said, let me turn the call over to Michael Brigham, President and CEO of Emusel Corporation, for opening remarks. Michael.

Great. Thank you, Joe, and good morning, everyone. So, yes, I would like to make a few opening comments. We are in the midst of a very positive transition right now at Emusel. Our investment to increase production capacity for the First Defense product line to support $30 million or more in revenue per year is now complete. For sure, this took longer than we had planned, as the process was plagued by certain contamination events and other challenges. That said, it is done, and we are in a good place going forward. With regards to our very long development timeline with Retain, we are now initiating investigational product use studies to test market acceptance in the field over the second half of the year. While, of course, we would prefer commercial sales under an FDA approval, we like to say that that we are going to get paid in data. This data will inform our exploration of strategic options and the future plan for this product as we continue to anticipate the FDA approval. So at this point, I'm going to turn this call over to Tim Fiore, our CFO, to review some second quarter financial highlights. Then I would like to offer a few comments from a strategic perspective, after which we will open the call for your questions. So, Tim?